TuisIONS • NASDAQ
add
Ionis Pharmaceuticals Inc
Vorige sluiting
$35,29
Dagwisseling
$35,49 - $36,95
Jaarwisseling
$23,95 - $52,34
Markkapitalisasie
5,85 mjd USD
Gemiddelde volume
1,51 m
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 131,61 m | 10,14% |
Bedryfskoste | 83,55 m | 39,85% |
Netto inkomste | -146,94 m | -2,90% |
Netto winsgrens | -111,64 | 6,58% |
Wins per aandeel | -0,92 | -20,52% |
EBITDA | -144,05 m | 1,56% |
Effektiewe belastingkoers | -0,08% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 2,15 mjd | -3,00% |
Totale bates | 2,81 mjd | 1,77% |
Totale aanspreeklikheid | 2,34 mjd | -5,28% |
Totale ekwiteit | 475,73 m | — |
Uitstaande aandele | 159,16 m | — |
Prys om te bespreek | 11,80 | — |
Opbrengs op bates | -12,62% | — |
Opbrengs op kapitaal | -14,71% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -146,94 m | -2,90% |
Kontant van bedrywe | -150,78 m | -0,56% |
Kontant van beleggings | 170,46 m | 123,98% |
Kontant van finansiering | 2,20 m | -90,67% |
Netto kontantverandering | 22,12 m | 143,90% |
Beskikbare kontantvloei | -107,97 m | -16,56% |
Meer oor
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has three commercially approved medicines: Spinraza, Tegsedi, and Waylivra, and has four drugs in pivotal studies: tominersen for Huntington's disease, tofersen for SOD1-ALS, AKCEA-APO-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.
The company was named Isis Pharmaceuticals until December 2015. Wikipedia
Gestig
1989
Hoofkwartier
Webwerf
Werknemers
1 069
